Alzamend Neuro ALZN

Jump To Section

    $

    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    .
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    +$0.02 (+2.78%)Past DayToday's Volume:
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    ,
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0

    Relative Strength Index (RSI)

    - The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.

    - The RSI is calculated using the following formula:

    RSI = 100 - (100 / (1 + RS))

    Where RS is the ratio of the average gains to the average losses over a specified period.

    - The default time period used is 14 days.

    - RSI values range between 0 and 100.

    RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)

    RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)

    RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.

    About

    Business overview of Alzamend Neuro (ALZN)
    Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.

    Key Insights

    Critical company metrics and information

    • Latest Closing Price

      $0.76

    • Market Cap

      $5.01 Million

    • Price-Earnings Ratio

      -1.90

    • Total Outstanding Shares

      5.43 Million Shares

    • Total Employees

      7

    • Dividend

      No dividend

    • IPO Date

      June 15, 2021

    • SIC Description

      Pharmaceutical Preparations

    • Primary Exchange

      NASDAQ

    • Type

      Common Stock

    • Headquarters

      3500 lenox rd. ne, Atlanta, GA, 30326

    • Homepage

      https://www.alzamend.com

    Historical Stock Splits

    If you bought 150 shares of ALZN before October 31, 2023, you'd have 1 share today.
    Execution DateSplit Amount
    July 16, 20241-for-10 (Reverse Split)
    October 31, 20231-for-15 (Reverse Split)

    Cash Flow Statement

    August 1, 2024 to October 31, 2024
    MetricValue
    Net Cash Flow, Continuing$3.72 Million
    Net Cash Flow From Financing Activities, Continuing$7.12 Million
    Net Cash Flow From Investing Activities$0
    Net Cash Flow From Investing Activities, Continuing$0
    Net Cash Flow From Operating Activities$-3.40 Million
    Net Cash Flow$3.72 Million

    Income Statement

    August 1, 2024 to October 31, 2024
    MetricValue
    Diluted Earnings Per Share$-0.40
    Diluted Average Shares$3.53 Million
    Basic Earnings Per Share$-0.40
    Income/Loss From Continuing Operations Before Tax$-1.36 Million
    Net Income/Loss$-1.36 Million
    Basic Average Shares$3.53 Million

    Comprehensive Income

    August 1, 2024 to October 31, 2024
    MetricValue
    Comprehensive Income/Loss Attributable To Noncontrolling Interest$0
    Comprehensive Income/Loss$-1.36 Million
    Other Comprehensive Income/Loss$0
    Comprehensive Income/Loss Attributable To Parent$-1.36 Million

    Balance Sheet

    August 1, 2024 to October 31, 2024
    MetricValue
    Noncurrent Liabilities$0
    Current Assets$4.77 Million
    Fixed Assets$240,976
    Noncurrent Assets$240,976
    Liabilities And Equity$5.01 Million
    Accounts Payable$1.25 Million

    Historical Dividends

    Announcement DatePayment DateRecord DateAmountFrequency
    No historical dividends

    Recent Headlines From The Web

    Latest news, press releases, and media coverage about ALZN from trusted financial sources
      Boost your savings and earn 4.15% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
      All TickersEarnings CalendarNews ArticlesAbout UsPrivacy & Cookies Info

      ⓒ 2025 Financhle. All Rights Reserved.